Diabetes Mellitus, Type 2 Clinical Trial
— TRIPODOfficial title:
A Randomized Trial to Slow the Progression of Diabetes (The TRIPOD Study)
Verified date | June 2023 |
Source | Duke-NUS Graduate Medical School |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The research objective of this one-year study is to test whether an evidence-based, low-cost mobile diabetes management package (DMP), with or without an incentive program grounded in economic theory (M-POWER Rewards), can effectively and cost-effectively improve health outcomes for adults with type 2 diabetes.
Status | Completed |
Enrollment | 269 |
Est. completion date | June 11, 2023 |
Est. primary completion date | June 8, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 70 Years |
Eligibility | All eligibility criteria will be self-declared. Inclusion Criteria: 1. Diagnosed with T2DM with suboptimal diabetes control as defined by a HbA1c level of between 7.5% and 11.0% (inclusive) at their most recent test taken within the past six calendar months. This HbA1c inclusion criterion will be based on the patients' self-reported HbA1c levels and test dates. 2. Not on insulin. 3. On at least one oral glucose-lowering drug. 4. Singapore Citizen or Permanent Resident with no plans to relocate during the study period. 5. Able to read, write, and communicate in English. 6. Own a personal smartphone and be able to use it. Exclusion Criteria: 1. Pregnant or lactating. 2. Diagnosed with chronic kidney disease (stage 3B with eGFR <45mL/min) or undergoing dialysis for end-stage kidney failure. 3. Diagnosed with liver cirrhosis. 4. Diagnosed with cancer that required treatment in the past five years. 5. Diagnosed with heart attack (i.e., acute myocardial infarction) within the past one year. 6. Diagnosed with heart failure (i.e., congestive heart failure) 7. Diagnosed with stroke or transient ischemic attacks. 8. Undergone whole blood or red blood cell transfusion within the past three months. 9. Diagnosed with severe anaemia (Haemoglobin <10g/dL) 10. Diagnosed with sickle-cell disease 11. Diagnosed with Thalassemia major 12. Undergone bariatric surgery or extensive bowel resection. 13. Undergone lower limb amputation (including toe amputation). 14. Taking systemic corticosteroids (including Traditional Chinese or Malay medicine). 15. Currently on doctor's advice against engaging in moderate-to-vigorous physical activity (i.e., brisk walking or more intense). 16. Currently have a condition(s) that restricts engaging in moderate-to-vigorous physical activity (i.e., brisk walking or more intense). |
Country | Name | City | State |
---|---|---|---|
Singapore | Duke-NUS Medical School | Singapore |
Lead Sponsor | Collaborator |
---|---|
Duke-NUS Graduate Medical School | Changi General Hospital, National Medical Research Council (NMRC), Singapore, Singapore General Hospital, SingHealth Polyclinics |
Singapore,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in HbA1c levels at Month 12 | HbA1c or glycated hemoglobin is a measure of blood glucose levels. HbA1c blood tests will be conducted at baseline and Month 12 and the difference will be calculated. | Baseline, Month 12 | |
Secondary | Change in HbA1c levels at Month 6 | HbA1c or glycated hemoglobin is a measure of blood glucose levels. HbA1c blood tests will be conducted at baseline and Month 6 and the difference between the follow-up assessment (Months 6) and baseline will be calculated. | Baseline, Month 6 | |
Secondary | Change in weight at Months 6 and 12 | Weight will be measured at baseline, Month 6, and Month 12. The difference in weight between each follow-up assessment (Months 6 and 12) and baseline will be calculated. | Baseline, Month 6, Month 12 | |
Secondary | Change in blood pressure at Months 6 and 12 | Blood pressure will be measured at baseline, Month 6, and Month 12. The difference in blood pressure between each follow-up assessment (Months 6 and 12) and baseline will be calculated. | Baseline, Month 6, Month 12 | |
Secondary | Proportion of participants that had insulin treatment initiated by Months 6 and 12 | Percentage of participants that had insulin treatment initiated by their diabetes care physician by each follow-up assessment (Months 6 and 12). | Baseline, Month 6, Month 12 | |
Secondary | Change in self-reported physical activity at Months 6 and 12 | Self-reported physical activity data will be collected at baseline, Month 6, and Month 12 via the Global Physical Activity Questionnaire (GPAQ). The difference in self-reported physical activity between each follow-up assessment (Months 6 and 12) and baseline will be calculated. | Baseline, Month 6, Month 12 | |
Secondary | Change in self-reported weight monitoring at Months 6 and 12 | Self-reported weight monitoring data will be collected at baseline, Month 6, and Month 12. The difference in self-reported weight monitoring between each follow-up assessment (Months 6 and 12) and baseline will be calculated. | Baseline, Month 6, Month 12 | |
Secondary | Change in self-reported blood glucose monitoring at Months 6 and 12 | Self-reported blood glucose monitoring data will be collected at baseline, Month 6, and Month 12. The difference in self-reported blood glucose monitoring between each follow-up assessment (Months 6 and 12) and baseline will be calculated. | Baseline, Month 6, Month 12 | |
Secondary | Change in self-reported medication adherence at Months 6 and 12 | Self-reported medication adherence data will be collected at baseline, Month 6, and Month 12. The difference in self-reported medication adherence between each follow-up assessment (Months 6 and 12) and baseline will be calculated. | Baseline, Month 6, Month 12 | |
Secondary | Change in self-reported diabetes self-management at Months 6 and 12 | Self-reported diabetes self-management data will be collected at baseline, Month 6, and Month 12 via the Diabetes Self-Management Questionnaire (DSMQ). The difference in self-reported diabetes self-management between each follow-up assessment (Months 6 and 12) and baseline will be calculated. | Baseline, Month 6, Month 12 | |
Secondary | Change in self-reported sleep quality at Months 6 and 12 | Self-reported sleep quality data will be collected at baseline, Month 6, and Month 12 via the Pittsburgh Sleep Quality Index (PSQI). The difference in self-reported sleep quality between each follow-up assessment (Months 6 and 12) and baseline will be calculated. | Baseline, Month 6, Month 12 | |
Secondary | Change in self-reported work productivity and daily activity impairment at Months 6 and 12 | Self-reported work productivity and daily activity impairment data will be collected at baseline, Month 6, and Month 12 via a modified Work Productivity and Activity Impairment: Specific Health Problem instrument (WPAI:SHP). The difference in self-reported work productivity and daily activity impairment between each follow-up assessment (Months 6 and 12) and baseline will be calculated. | Baseline, Month 6, Month 12 | |
Secondary | Change in self-reported health utility index at Months 6 and 12 | Self-reported health utility index data will be collected at baseline, Month 6, and Month 12 via the EQ-5D-5L questionnaire. The difference in self-reported health utility index between each follow-up assessment (Months 6 and 12) and baseline will be calculated. | Baseline, Month 6, Month 12 | |
Secondary | Incremental cost-effectiveness ratios based on HbA1c at Month 12 | Incremental cost-effectiveness ratios will be determined by calculating the incremental cost per unit reduction in HbA1c at Month 12 (primary endpoint) compared to baseline. | Baseline, Month 12 | |
Secondary | Incremental cost-effectiveness ratios based on QALY at Month 12 | Incremental cost-effectiveness ratios will be determined by calculating the incremental cost per quality adjusted life year (QALY) gained at Month 12 (primary endpoint) compared to baseline. | Baseline, Month 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |